1-3 of 3
Olle Larsson
Close
Sort by
Journal Articles

Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model

Eline Menu, Helena Jernberg-Wiklund, Thomas Stromberg, Hendrik De Raeve, Leonard Girnita, Olle Larsson, Magnus Axelson, Kewal Asosingh, Kenneth Nilsson, Ben Van Camp, Karin Vanderkerken
Journal: Blood
Blood (2006) 107 (2): 655–660.
https://doi.org/10.1182/blood-2005-01-0293
Published: 2006
Journal Articles

IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G 2 /M-phase accumulation and apoptosis in multiple myeloma cells

Thomas Strömberg, Simon Ekman, Leonard Girnita, Lina Y. Dimberg, Olle Larsson, Magnus Axelson, Johan Lennartsson, Ulf Hellman, Kristina Carlson, Anders Österborg, Karin Vanderkerken, Kenneth Nilsson, Helena Jernberg-Wiklund
Journal: Blood
Blood (2006) 107 (2): 669–678.
https://doi.org/10.1182/blood-2005-01-0306
Published: 2006
Includes: Supplemental data
Journal Articles

Targeting the Insulin-Like Growth Factor-I Receptor (IGF-IR) in Multiple Myeloma Cells Using Selective IGF-IR Tyrosine Kinase Inhibitors.

Thomas Stromberg, PhD, Simon Ekman, MD, PhD, Leonard Girnita, PhD, Johan Lennartsson, Ulf Hellman, PhD, Kristina Carlson, MD, PhD, Anders Osterborg, MD, PhD, Karin Vanderkerken, PhD, Magnus Axelson, MD, PhD, Olle Larsson, MD, PhD, Kenneth Nilsson, MD, PhD, Helena Jernberg-Wiklund, PhD
Journal: Blood
Blood (2004) 104 (11): 639.
https://doi.org/10.1182/blood.V104.11.639.639
Published: 2004